dnph1 Antibody

Basic Research Questions

• What is DNPH1 and why is it significant in cancer research?

  DNPH1 (2'-deoxynucleoside 5'-phosphate N-hydrolase 1) is a crucial protein involved in DNA repair processes, specifically functioning as a "nucleotide sanitizer" that prevents the incorporation of abnormal nucleotides into DNA. Research has established that DNPH1 eliminates cytotoxic nucleotide 5-hydroxymethyl-deoxyuridine (hmdU) monophosphate from the nucleotide pool . Its significance in cancer research stems from its role in potentiating the sensitivity of BRCA-deficient cells to PARP inhibitors (PARPi), with inhibition of DNPH1 showing promise as a strategy for hypersensitization of BRCA-deficient cancers to PARPi therapy . DNPH1 has been identified as a c-Myc target and is overexpressed in various tumors , making it a valuable research target for understanding cancer mechanisms and developing novel therapeutic approaches.

• What are the typical applications for DNPH1 antibodies in research?

  DNPH1 antibodies are predominantly utilized in several key applications:

  Application	Typical Dilution	Verified Samples
  Western Blotting (WB)	1:500-1:2000	Human heart, 293T, BT-474
  Immunohistochemistry (IHC)	1:50-1:200	Human liver cancer, Human tonsil
  ELISA	1:40000	Various human samples
  Immunofluorescence/Immunocytochemistry (IF/ICC)	1:50-1:200	Human cell lines

  These applications enable researchers to detect DNPH1 protein expression, localization, and interactions in various experimental contexts, particularly in studies examining DNA repair mechanisms, nucleotide metabolism, and cancer biology .

• What are the characteristics of a high-quality DNPH1 antibody?

  A high-quality DNPH1 antibody should demonstrate:

  • Specificity: Recognizes human DNPH1 (and potentially mouse DNPH1, depending on reactivity)

  • Appropriate molecular weight detection: Typically observes DNPH1 at approximately 19-20 kDa

  • Cellular localization detection: Ability to detect DNPH1 in both nuclear and cytoplasmic compartments

  • Low background: Minimal non-specific binding in both Western blot and immunohistochemistry applications

  • Consistent performance: Reproducible results across different experimental conditions and sample types

  • Validated reactivity: Confirmed detection in relevant human samples (e.g., heart, liver cancer, tonsil tissue)

  When evaluating an antibody, researchers should review validation data and consider the specific immunogen used for antibody production, as this affects epitope recognition and performance in different applications .

• What are the optimal storage and handling conditions for DNPH1 antibodies?

  For maximum stability and performance of DNPH1 antibodies, implement the following storage and handling protocols:

  • Long-term storage: Store at -20°C in small aliquots to prevent freeze/thaw cycles, which can degrade antibody quality

  • Short-term storage: For immediate use (typically within 1 week), store at 2-8°C

  • Formulation: Most DNPH1 antibodies are supplied in PBS containing stabilizers such as 0.02% sodium azide and/or 50% glycerol

  • Avoid repeated freeze/thaw cycles: Limit to ≤5 cycles to preserve antibody function and specificity

  • Working dilution preparation: Prepare fresh working dilutions on the day of the experiment whenever possible

  • Shipping conditions: Typically shipped with ice packs; upon receipt, immediately transfer to recommended storage temperature

  Following these guidelines will help maintain antibody performance and extend shelf life, which is typically one year from date of dispatch when properly stored .

• What controls should be included when working with DNPH1 antibodies?

  Implementing appropriate controls is crucial for validating DNPH1 antibody experiments:

  • Positive tissue/cell controls: Use human heart, 293T, or BT-474 cells, which have been verified as positive samples for DNPH1 expression

  • Negative controls: Include antibody diluent without primary antibody to assess background

  • DNPH1 knockout/knockdown samples: If available, use DNPH1-/- cell lines (such as those generated via CRISPR-Cas9) as specificity controls

  • Loading controls: For Western blots, include housekeeping proteins (β-actin, GAPDH) to normalize protein loading

  • Peptide competition: Pre-incubate the antibody with the immunizing peptide to confirm specificity

  • Isotype controls: Use matched IgG concentration from the same host species (typically rabbit IgG) to control for non-specific binding

  These controls help validate antibody specificity and experimental results, particularly important when investigating DNPH1's role in complex cellular processes.

Advanced Research Questions

• How can DNPH1 antibodies be used to investigate synthetic lethality in BRCA-deficient cancer cells?

  DNPH1 antibodies serve as critical tools for exploring synthetic lethality mechanisms in BRCA-deficient cancer cells through several sophisticated experimental approaches:

  • Protein expression analysis: Use Western blotting with DNPH1 antibodies to quantify protein levels before and after PARP inhibitor treatment in BRCA1/2-deficient versus proficient cells

  • Chromatin association studies: Employ fractionation techniques followed by immunoblotting to detect PARP1 trapping on chromatin in the presence or absence of DNPH1, revealing the molecular mechanism of synthetic lethality

  • Immunofluorescence co-localization: Combine DNPH1 antibodies with DNA damage markers (γH2AX) to visualize the spatiotemporal dynamics of DNA repair in response to combined DNPH1 inhibition and PARPi treatment

  • Proximity ligation assays: Detect in situ protein-protein interactions between DNPH1 and components of DNA repair pathways

  • ChIP-seq applications: Use chromatin immunoprecipitation with DNPH1 antibodies to identify genomic binding sites related to DNA repair processes

  Research has shown that DNPH1 inhibition potentiates PARP inhibitor sensitivity through increased genomic hmdU incorporation, leading to SMUG1 glycosylase action, PARP trapping, replication fork collapse, and ultimately apoptosis in BRCA-deficient cells . DNPH1 antibodies enable detection of these molecular events, providing insights into synthetic lethal mechanisms and potential therapeutic strategies.

• What methodological considerations are important when examining DNPH1's role in nucleotide metabolism?

  Investigating DNPH1's function in nucleotide metabolism requires careful methodological planning:

  • Metabolomic profiling: Combine DNPH1 immunoprecipitation with mass spectrometry to identify physiological substrates. Research has identified hmdUMP as DNPH1's primary biological target, with DNPH1-/- cells showing ~3-fold increase in genomic hmdU compared to wild-type cells

  • Enzyme activity assays: Measure DNPH1 hydrolase activity using purified protein and synthetic nucleotide substrates. Time-resolved 1H NMR spectroscopy has shown DNPH1 preferentially hydrolyzes hmdUMP compared to canonical dNMPs

  • Nucleotide incorporation analysis: Use DNPH1 antibodies to correlate protein levels with nucleotide incorporation rates:

    Cell Type	Genomic hmdU (per million dN)	Fold Increase vs. WT
    Wild-type	~5	1×
    DNPH1-/-	~15	3×
    DNPH1-/- + hmdU treatment	~45	9×

  • Complementation studies: Re-express wild-type or mutant DNPH1 in knockout backgrounds to establish structure-function relationships

  • DNPH1-interactome mapping: Use co-immunoprecipitation with DNPH1 antibodies followed by mass spectrometry to identify protein interaction networks involved in nucleotide metabolism

  Research has established that DNPH1 functions primarily as a nucleotide sanitizer that hydrolyzes hmdUMP to prevent its incorporation into DNA, with implications for genomic stability and cellular responses to PARP inhibitors .

• How can researchers validate the specificity of DNPH1 antibodies in their experimental models?

  Comprehensive validation of DNPH1 antibody specificity requires a multi-faceted approach:

  • Genetic knockout validation: Generate CRISPR-Cas9 mediated DNPH1-/- cell lines and confirm loss of signal in Western blot, IHC, or IF applications

  • siRNA/shRNA knockdown: Perform transient or stable knockdown of DNPH1 and demonstrate corresponding reduction in antibody signal

  • Antibody neutralization: Pre-incubate antibody with immunizing peptide or recombinant DNPH1 protein before application to demonstrate signal extinction

  • Cross-species reactivity testing: Evaluate antibody performance across different species samples based on sequence homology and epitope conservation

  • Multi-antibody concordance: Compare results using antibodies targeting different epitopes of DNPH1:

    Antibody Product	Epitope Region	Applications	Host	Specificity Profile
    CAB2382	aa 75-174	WB, IF/ICC, ELISA	Rabbit	Human, Mouse
    E-AB-19145	Fusion protein	WB, IHC	Rabbit	Human
    TA359861	C-terminal region	WB	Rabbit	Human

  • Mass spectrometry validation: Perform immunoprecipitation followed by MS analysis to confirm antibody captures DNPH1 and assess potential cross-reactivity

  Thorough validation ensures experimental findings genuinely reflect DNPH1 biology rather than artifacts from non-specific antibody interactions, particularly important when investigating DNPH1's subtle regulatory roles in nucleotide metabolism pathways .

• What are the challenges in detecting DNPH1 subcellular localization using antibody-based techniques?

  Accurately determining DNPH1 subcellular localization presents several technical challenges that researchers must address:

  • Dual localization pattern: DNPH1 exhibits both nuclear and cytoplasmic localization , requiring careful optimization of fixation and permeabilization protocols to preserve both pools

  • Low endogenous expression levels: DNPH1 is expressed at relatively low levels in many tissues, including brain, colon, lung, and peripheral blood leukocytes , necessitating sensitive detection methods

  • Fixation-dependent epitope masking: Different fixation methods (paraformaldehyde vs. methanol) may affect antibody accessibility to DNPH1 epitopes

  • Cell type-specific expression patterns: DNPH1 expression varies across cell types, with notable expression in cancer cell lines like 293T and BT-474

  • Dynamic translocation: DNPH1 may shuttle between compartments based on cellular conditions or DNA damage

  To overcome these challenges, researchers should:

  • Optimize antibody concentration (typically 1:50-1:200 for IF/ICC)

  • Compare multiple fixation and permeabilization protocols

  • Validate subcellular localization using biochemical fractionation followed by Western blot

  • Include co-staining with established subcellular markers (nuclear lamins, cytoskeletal proteins)

  • Employ super-resolution microscopy techniques for precise localization

  Understanding DNPH1's exact subcellular distribution is critical for elucidating its function in nucleotide metabolism and DNA repair pathways in both normal and cancer cells .

• How can DNPH1 antibodies be utilized to investigate resistance mechanisms to PARP inhibitors?

  DNPH1 antibodies offer powerful tools for exploring PARP inhibitor resistance mechanisms:

  • Expression correlation studies: Quantify DNPH1 protein levels in matched pre-treatment and post-resistance tumor samples using IHC or Western blot

  • Functional pathway analysis: Use DNPH1 antibodies in combination with other DNA repair markers to map pathway alterations in resistant cells

  • Chromatin dynamics investigation: Monitor PARP trapping and chromatin association of DNPH1 and DNA repair factors during resistance development

  • Genetic complementation assays: Re-express wild-type or mutant DNPH1 in knockout backgrounds to determine structural requirements for PARPi sensitivity

  • Combination therapy testing: Use DNPH1 antibodies to monitor protein changes during combination treatments designed to overcome resistance:

    Treatment Condition	PARP Trapping	γH2AX Signaling	Apoptosis Markers	Clinical Implication
    PARPi alone	Moderate	Moderate	Low in resistant cells	Initial therapy
    hmdU + PARPi	Enhanced	Enhanced	Moderate	Sensitization strategy
    DNPH1 inhibition + PARPi	Enhanced	Enhanced	High	Resistance reversal
    SMUG1 depletion + PARPi	Reduced	Reduced	Low	Resistance mechanism

  Research has demonstrated that BRCA1-deficient cells acquiring resistance to PARPi can be re-sensitized through treatment with hmdU and DNPH1 inhibition . This re-sensitization occurs because genomic hmdU is a key determinant of PARPi sensitivity, with SMUG1 glycosylase action on genomic hmdU leading to PARP trapping and subsequent cell death . DNPH1 antibodies enable researchers to track these molecular events and identify potential therapeutic vulnerabilities in resistant tumors.

Experimental Methodology Questions

• What are the recommended protocols for optimizing DNPH1 antibody performance in Western blotting?

  Optimizing Western blot protocols for DNPH1 detection requires attention to several critical parameters:

  • Sample preparation:

    • Extract proteins using RIPA buffer supplemented with protease inhibitors

    • Include phosphatase inhibitors if examining post-translational modifications

    • Determine optimal protein loading (typically 20-40 μg per lane)

  • Gel electrophoresis considerations:

    • Use 12-15% polyacrylamide gels for optimal resolution of DNPH1 (19-20 kDa)

    • Include molecular weight markers that precisely cover the 15-25 kDa range

  • Antibody dilution optimization:

    • Recommended dilution range: 1:500-1:2000

    • Test multiple dilutions in a gradient to determine optimal signal-to-noise ratio

    • Prepare antibodies in 5% non-fat dry milk or BSA in TBST

  • Incubation conditions:

    • Primary antibody: Overnight at 4°C or 2 hours at room temperature

    • Secondary antibody: 1 hour at room temperature (typically HRP-conjugated anti-rabbit IgG)

  • Signal detection optimization:

    • For low abundance samples, use enhanced chemiluminescence (ECL) substrates with increased sensitivity

    • Optimize exposure times to prevent signal saturation

    • Consider fluorescent secondary antibodies for more precise quantification

  Researchers should note that DNPH1 bands may sometimes appear at positions slightly different from the calculated 19 kDa due to post-translational modifications or sample preparation conditions . Verified positive control samples include human heart tissue, 293T, and BT-474 cell lines .

• How can DNPH1 antibodies be effectively employed to study the interplay between nucleotide metabolism and DNA repair?

  DNPH1 antibodies can be strategically used to investigate the intersection of nucleotide metabolism and DNA repair through several sophisticated approaches:

  • Colocalization studies with DNA repair factors:

    • Perform dual immunofluorescence with DNPH1 and DNA repair proteins (PARP1, BRCA1/2, SMUG1)

    • Analyze recruitment dynamics to DNA damage sites induced by various genotoxic agents

    • Quantify colocalization coefficients under different treatment conditions

  • Chromatin immunoprecipitation (ChIP) analysis:

    • Use DNPH1 antibodies to identify genomic regions where DNPH1 may function

    • Compare binding patterns before and after DNA damage induction

    • Correlate with regions of active DNA repair or replication

  • Protein complex isolation:

    • Perform immunoprecipitation with DNPH1 antibodies to isolate associated protein complexes

    • Identify interacting partners involved in nucleotide metabolism and DNA repair

    • Validate interactions using reverse co-IP, proximity ligation assays, or FRET

  • Functional pathway mapping:

    • Combine DNPH1 immunostaining with nucleotide incorporation assays (EdU, BrdU)

    • Track replication fork dynamics in the presence or absence of DNPH1

    • Correlate DNPH1 levels with replication stress markers

  Research has established that DNPH1 functions at the intersection of these pathways by preventing incorporation of modified nucleotides (particularly hmdU) into DNA, which would otherwise lead to SMUG1-mediated base excision, PARP trapping, and replication fork collapse . This mechanism underlies the synthetic lethality observed in BRCA-deficient cells treated with PARP inhibitors and provides a promising therapeutic strategy for cancer treatment.

• What approaches can be used to quantify DNPH1 expression levels in patient-derived samples?

  Quantifying DNPH1 expression in patient samples requires carefully optimized methodologies:

  • Immunohistochemistry (IHC) quantification:

    • Use validated DNPH1 antibodies at optimized dilutions (typically 1:50-1:200)

    • Implement digital pathology platforms for objective quantification

    • Score intensity (0-3+) and percentage of positive cells to derive H-scores or Allred scores

    • Include appropriate positive controls (human liver cancer, tonsil)

  • Multiplex immunofluorescence:

    • Combine DNPH1 antibodies with markers for cell types or signaling pathways

    • Use spectral unmixing to distinguish multiple fluorophores

    • Perform automated single-cell quantification of DNPH1 intensity across tissue regions

  • Tissue microarray (TMA) analysis:

    • Standardize DNPH1 detection across multiple patient samples simultaneously

    • Correlate expression with clinicopathological features and outcomes

    • Establish scoring criteria specific for DNPH1 expression patterns

  • Liquid biopsy approaches:

    • Detect DNPH1 in circulating tumor cells using immunocytochemistry

    • Analyze DNPH1 in extracellular vesicles from patient plasma

    • Correlate with disease progression or treatment response

  When analyzing patient samples, researchers should consider that DNPH1 is overexpressed in various tumors as a c-Myc target , making it potentially valuable as a biomarker for certain cancer types or as an indicator of potential response to therapies targeting nucleotide metabolism or DNA repair pathways.

• How do different DNPH1 antibody clones compare in detecting specific protein isoforms or post-translational modifications?

  Different DNPH1 antibody clones exhibit varying capabilities for detecting specific protein isoforms and post-translational modifications:

  Antibody Clone	Epitope Region	Isoform Detection	PTM Sensitivity	Species Reactivity	Notes on Performance
  Polyclonal (N-terminal)	aa 1-75	May detect multiple isoforms	Varies by lot	Human	Better for detecting N-terminal variants
  Monoclonal (CAB2382)	aa 75-174	Specific isoform detection	Less affected by PTMs in epitope region	Human, Mouse	Consistent lot-to-lot performance
  Polyclonal (C-terminal)	C-terminal region	May miss C-terminal truncated variants	Sensitive to C-terminal modifications	Human	Useful for detecting full-length protein
  Full-length protein	Multiple epitopes	Detects most isoforms	Variable sensitivity	Human	Highest sensitivity but potential cross-reactivity

  When selecting an antibody:

  • For detecting specific DNPH1 isoforms, choose antibodies targeting regions that differ between isoforms

  • For phosphorylation studies, avoid antibodies whose epitopes contain potential phosphorylation sites

  • Consider using multiple antibodies targeting different epitopes to validate findings

  • Review validation data showing the observed molecular weight (typically 19-20 kDa)

  Research indicates that two alternative transcripts encoding different DNPH1 proteins have been described , making antibody selection critical for accurately characterizing DNPH1 expression in experimental systems.

• What considerations are important when designing experiments to study DNPH1's role in cancer drug resistance?

  Designing robust experiments to investigate DNPH1's role in cancer drug resistance requires careful planning across multiple dimensions:

  • Cell line selection:

    • Include matched sensitive/resistant pairs (e.g., parental and PARPi-resistant BRCA1/2-deficient lines)

    • Incorporate cell lines with different BRCA mutation status (BRCA1-mut, BRCA2-mut, BRCA-proficient)

    • Consider patient-derived xenograft (PDX) models that maintain tumor heterogeneity

  • Genetic manipulation approaches:

    • Generate CRISPR-Cas9 DNPH1 knockout lines with appropriate controls

    • Create isogenic lines expressing wild-type vs. catalytically inactive DNPH1 (E104A mutant)

    • Use inducible systems to modulate DNPH1 expression temporally

  • Functional assays:

    • Measure synthetic lethality using combination drug treatments

    • Assess DNA damage response through γH2AX foci formation, comet assays

    • Quantify PARP trapping on chromatin after various treatments

    • Analyze cell cycle progression and apoptosis markers

  • Biochemical analyses:

    • Quantify genomic hmdU incorporation in different experimental conditions:

      Experimental Condition	Expected Genomic hmdU	PARPi Sensitivity
      Wild-type cells	Baseline	Moderate
      DNPH1-/- cells	Increased (3×)	Enhanced
      DNPH1-/- + hmdU treatment	Highly increased (9×)	Greatly enhanced
      DNPH1-/- + SMUG1-/-	Increased but not toxic	Resistant

    • Measure enzyme activities of related pathway components (SMUG1, DCTD, TET1/2)

  Research has demonstrated that BRCA1-deficient cells that acquired resistance to PARPi could be re-sensitized by treatment with hmdU and DNPH1 inhibition , highlighting the potential of targeting DNPH1 as a strategy to overcome therapy resistance in cancer.